Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture.
Eriksen EF, Lyles KW, Colón-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P. Eriksen EF, et al. Among authors: mesenbrink p. J Bone Miner Res. 2009 Jul;24(7):1308-13. doi: 10.1359/jbmr.090209. J Bone Miner Res. 2009. PMID: 19257818 Free PMC article. Clinical Trial.
The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair.
Colón-Emeric CS, Caminis J, Suh TT, Pieper CF, Janning C, Magaziner J, Adachi J, Rosario-Jansen T, Mesenbrink P, Horowitz ZD, Lyles KW; HORIZON Recurrent Fracture Trial. Colón-Emeric CS, et al. Among authors: mesenbrink p. Curr Med Res Opin. 2004 Jun;20(6):903-10. doi: 10.1185/030079904125003683. Curr Med Res Opin. 2004. PMID: 15200749 Clinical Trial.
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Black DM, et al. Among authors: mesenbrink p. N Engl J Med. 2007 May 3;356(18):1809-22. doi: 10.1056/NEJMoa067312. N Engl J Med. 2007. PMID: 17476007 Free article. Clinical Trial.
Zoledronic acid and clinical fractures and mortality after hip fracture.
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Lyles KW, et al. Among authors: mesenbrink p. N Engl J Med. 2007 Nov 1;357(18):1799-809. doi: 10.1056/NEJMoa074941. Epub 2007 Sep 17. N Engl J Med. 2007. PMID: 17878149 Free PMC article. Clinical Trial.
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF. Recker RR, et al. Among authors: mesenbrink p. J Bone Miner Res. 2008 Jan;23(1):6-16. doi: 10.1359/jbmr.070906. J Bone Miner Res. 2008. PMID: 17892374 Free article. Clinical Trial.
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF; Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group. Grbic JT, et al. Among authors: mesenbrink p. J Am Dent Assoc. 2008 Jan;139(1):32-40. doi: 10.14219/jada.archive.2008.0017. J Am Dent Assoc. 2008. PMID: 18167382 Clinical Trial.
47 results